Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Exploring subacute effects of a DMT and harmine meditation retreat on the brain's control energy landscapebioRxiv · 2026-11-11Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-11-10Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterClinicalTrials.gov · 2026-11-10Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-11-09Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive DisorderClinicalTrials.gov · 2026-11-06Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-11-06A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?ClinicalTrials.gov · 2026-11-06Psilocybin for Amblyopia - Targeting Critical Periods in Humans (PATCH)ClinicalTrials.gov · 2026-11-05Pilot Study of Psilocybin-assisted Treatment for Cannabis Use DisorderClinicalTrials.gov · 2026-11-05Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-11-05Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2026-11-05A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-11-05A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainClinicalTrials.gov · 2026-11-04TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-11-03TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-11-03NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-11-03Psilocybin FCR Early-Stage Breast CancerClinicalTrials.gov · 2026-11-02PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-11-02Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary AnalysisJournal of Pain and Symptom Management · 2026-11-01Psychedelics restructure information in the human brainbioRxiv · 2026-10-31Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed micebioRxiv · 2026-10-31Psilocybin as a novel drug in the treatment of major depressive disorder: a systematic reviewMedical Science · 2026-10-30Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-10-30Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.Journal of affective disorders · 2026-10-30Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-10-30A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-10-29An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderClinicalTrials.gov · 2026-10-29Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-10-27Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among VeteransClinicalTrials.gov · 2026-10-26Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.JAMA · 2026-10-26Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-10-26Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-10-23A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-10-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-10-21A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-10-20Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-10-20A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-10-19The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of PsilocybinClinicalTrials.gov · 2026-10-16Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-10-16Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.ClinicalTrials.gov · 2026-10-16Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways.CNS & neurological disorders drug targets · 2026-10-14Group psilocybin in an integrative retreat setting enhances social connection: an observational case reportPsyArXiv · 2026-10-14A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced CancerClinicalTrials.gov · 2026-10-14An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-10-13Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb PainClinicalTrials.gov · 2026-10-09Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-10-09Pilot Study on the Effects of Psilocybin on Belief Updating and Insight FormationClinicalTrials.gov · 2026-10-08Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.British journal of clinical pharmacology · 2026-10-01The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSDClinicalTrials.gov · 2026-10-01Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats.Neuroscience bulletin · 2026-10-01The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-09-28Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-09-24Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-09-23ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-09-22A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy AdultsPharmaceuticals · 2026-09-21Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.British journal of clinical pharmacology · 2026-09-21Psilocybin in the Treatment of Methamphetamine Use DisorderClinicalTrials.gov · 2026-09-21Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.Mini reviews in medicinal chemistry · 2026-09-18A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-09-16PRoMiSS: Psilocybin and the Role of Music in Set and SettingClinicalTrials.gov · 2026-09-15Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual AnhedoniaClinicalTrials.gov · 2026-09-15Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-09-14A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-09-09Effects of Psilocybin in Obsessive Compulsive DisorderClinicalTrials.gov · 2026-09-04Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseClinicalTrials.gov · 2026-09-04Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-09-04Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-09-04Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in RemissionClinicalTrials.gov · 2026-09-04Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot StudyClinicalTrials.gov · 2026-09-03Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-09-02Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-09-02Patterns of Psychedelic Use in Italy: Insights from the Global Psychedelic SurveyClinical Neuropsychopharmacology and Addiction · 2026-09-01Psilocybin collapses visual change detection and drives cortical dynamics toward a state of surprisebioRxiv · 2026-08-25Toward an Optimal Framework for Psilocybin Regulation: A Comparison of State Regulatory Approaches Across Key Dimensions.The Journal of legal medicine · 2026-08-25An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal CancersClinicalTrials.gov · 2026-08-19Psychedelics align brain activity with context.Nature · 2026-08-19The Abuse Liability of Classic Psychedelics: A Methodological Critique and Assessment of the Quality of Evidence of Recent StudiesCurrent Addiction Reports · 2026-08-18Safety for Home Administration of Microdose Psilocybin UseClinicalTrials.gov · 2026-08-14Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertaintybioRxiv · 2026-08-13Processing Intergenerational Trauma With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-08-13The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderClinicalTrials.gov · 2026-08-13PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-08-13Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisClinicalTrials.gov · 2026-08-11An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)ClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-08-07Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic TherapyClinicalTrials.gov · 2026-08-06Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanismsBehavioural Pharmacology · 2026-08-01Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.Hearing research · 2026-08-01Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSDClinicalTrials.gov · 2026-07-29A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-23Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-07-17Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-16Shurooms: The First Ethnomycological Study from Within the African Initiatory Tradition - Ewe, Soma, and the Ceremonial Architecture of Psilocybin Healing (N = 300+)Zenodo (CERN European Organization for Nuclear Research) · 2026-07-14Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainClinicalTrials.gov · 2026-07-10The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-09Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use DisorderClinicalTrials.gov · 2026-07-09Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)ClinicalTrials.gov · 2026-07-07Surprising Variability in Tryptamine Profiles of Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions.Journal of fungi (Basel, Switzerland) · 2026-07-02A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-07-01Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine & Surgery · 2026-07-01Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.JAMA psychiatry · 2026-07-01Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-07-01Psychedelics as a potential treatment for borderline personality disorder: A narrative review.Psychiatry research · 2026-07-01Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”PLOS One · 2026-06-305-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy.Nature communications · 2026-06-24Psilocybin-Assisted Therapy for Prolonged GriefClinicalTrials.gov · 2026-06-23Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-22The Acute Effects of Psilocybin on Cognition, Memory, and Brain FunctionClinicalTrials.gov · 2026-06-15Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled StudyClinicalTrials.gov · 2026-06-042 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy VolunteersClinicalTrials.gov · 2026-06-04Comparing Cannabis Use Motivations and Dependence Across Regular Cannabis Users Who Have or Have Not Recently Used Psilocybin.Cannabis and cannabinoid research · 2026-06-01Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [F]FDG-PET study.Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026-06-01Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headacheJournal of Psychopharmacology · 2026-05-29Group Psilocybin-Assisted Therapy for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-05-22A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for DepressionClinicalTrials.gov · 2026-05-20Psilocybin-assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-05-19Psilocybin-facilitated Treatment for Cocaine UseClinicalTrials.gov · 2026-05-18Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)ClinicalTrials.gov · 2026-05-14Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2026-05-12Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleClinicalTrials.gov · 2026-05-12A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerClinicalTrials.gov · 2026-05-06Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot StudyClinicalTrials.gov · 2026-05-06A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive DisorderClinicalTrials.gov · 2026-05-06A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive DisorderClinicalTrials.gov · 2026-05-04PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554)The Journal of Pharmacology and Experimental Therapeutics · 2026-05-01The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.The British journal of psychiatry: the journal of mental science · 2026-05-01Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.Cancer reports (Hoboken, N.J.) · 2026-05-01Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled SettingsRepository for Publications and Research Data (ETH Zurich) · 2026-04-30Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesiaCommunications Biology · 2026-04-24Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderClinicalTrials.gov · 2026-04-22A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-04-22Psilocybin reshapes cortical inhibition through selective interneuron recruitment.bioRxiv: the preprint server for biology · 2026-04-17Additional file 1 of Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depressionFigshare · 2026-04-09Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depressionBMC Medical Education · 2026-04-09Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use DisorderClinicalTrials.gov · 2026-04-07A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depressionNature Mental Health · 2026-04-06Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury.Molecular psychiatry · 2026-04-01Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.Headache · 2026-04-01Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studiesReligion Brain & Behavior · 2026-03-31Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory DepressionClinicalTrials.gov · 2026-03-27Psychedelic Experiences and Finitude in Serious Illness: A Qualitative SynthesisJournal of Pain and Symptom Management · 2026-03-26Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distributionCanadian Journal of Public Health · 2026-03-19Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderClinicalTrials.gov · 2026-03-13Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.BMJ open · 2026-03-12Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional HealthClinicalTrials.gov · 2026-03-11Psilocybin-facilitated Treatment for Chronic PainClinicalTrials.gov · 2026-03-11Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.ClinicalTrials.gov · 2026-03-05Study of Psilocybin for Anorexia in Young AdultsClinicalTrials.gov · 2026-03-03Meaning and Psychedelics in Palliative Care: A Narrative Review.Journal of pain and symptom management · 2026-03-01Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence.Exploratory research in clinical and social pharmacy · 2026-03-01The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?Psychiatric Research and Clinical Practice · 2026-03-01Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.BMJ supportive & palliative care · 2026-02-27Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-02-23Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23Delayed psilocybin treatment after repeated mild traumatic brain injury recovers chronic behavioural deficits, reduces microglial density, and enhances hippocampal neurogenesis in ratsResearch Square · 2026-02-23Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical TrialResearch Square · 2026-02-23Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH StudyClinicalTrials.gov · 2026-02-17Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials.Neuropharmacology · 2026-02-15Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityClinicalTrials.gov · 2026-02-13Psilocybin-Assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-02-12Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control DesignClinicalTrials.gov · 2026-02-05A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone TreatmentClinicalTrials.gov · 2026-01-23The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing TraumaClinicalTrials.gov · 2026-01-22Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Journal of affective disorders · 2026-01-15From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.Translational behavioral medicine · 2026-01-07Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild StressJournal of Psychoactive Drugs · 2026-01-02Reported Safety Practices of Publicly Advertised Psychedelic Retreats.JAMA network open · 2026-01-02Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trialNeuroscience Applied · 2026-01-01An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomesNeuroscience Applied · 2026-01-01Mismatch between psilocybin-induced head-twitch behaviour and psilocin brain levels in miceNeuroscience Applied · 2026-01-01Behavioral and neuronal effects of psilocybin in miceNeuroscience Applied · 2026-01-01Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.Journal of AOAC International · 2026-01-01Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.Journal of psychopharmacology (Oxford, England) · 2026-01-01Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.Current topics in behavioral neurosciences · 2026-01-01The Effect of Magic Mushroom (Psilocybe azurescens) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors.Journal of neuroscience research · 2026-01-01Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.Annals of medicine and surgery (2012) · 2026-01-01Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.Therapeutic advances in psychopharmacology · 2026-01-01Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure RisksAuthorea Preprints · 2025-12-29The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationClinicalTrials.gov · 2025-12-24Wherefore the magic? The evolutionary role of psilocybin in naturebioRxiv · 2025-12-19Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.BJPsych open · 2025-12-15Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats.Behavioural pharmacology · 2025-12-01Psilocybin vs Ketamine for Alcohol Use DisorderClinicalTrials.gov · 2025-11-28Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderClinicalTrials.gov · 2025-11-26